Company intelligence / Profile preview

Intrexon Energy

Germantown, Maryland, United States

Ownership: Private
Development stage: Other

Overview

Precigen (formerly Intrexon) applies proprietary synthetic biology platforms to gene therapy, cell therapy, energy, agricultural, and environmental biotechnology. Its most advanced human therapeutic asset is PRGN-3006 (a CAR-T therapy for AML, in Phase 1/2). Energy-focused programs (Intrexon Energy Partners) center on engineered microbes for fuels/chemicals, but have not reached commercial product stage[2][4][5].

Therapeutic areas: HematologyOncologyOtherRare Diseases
Modalities: Gene therapyCell therapySynthetic biology platformCAR-T cell therapyMicrobial therapyGenetic engineeringSmall molecule
Industry: Non-Drug Biotech

Partnerships

Johnson & JohnsonMerck SeronoMD Anderson Cancer CenterUniversity of MinnesotaStrategic joint ventures and ECCs with agriculture, industrial, and energy firms

Beyond the preview

Go deeper on Intrexon Energy.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intrexon Energy.

Explore the full profile